MolecuLight has reported that the use of its MolecuLight i:X device to view the presence of increased bacterial burden in wounds raised 12-week healing rates by 204% in a trial involving diabetic foot ulcer patients.
The randomised, independent, blinded, controlled trial enrolled 56 patients to assess the use of point-of-care bacterial autofluorescence imaging to manage diabetic foot ulcers versus the standard-of-care alone.
